Evidence map›Paper›PMID 40083706›Full record

ArticleInternational journal of biological sciences2025

BRD7 Inhibited Immune Escape in Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.

Yilin Guo, Jiaxue Lu, Xiaoxu Li, Shiqi Yan, Jieyu Zhou, Ziying Tian, Ying Liu, Nan Li, Qing Zhou, Xiayu Li and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yilin GuoDepartment of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jiaxue LuDepartment of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiaoxu LiDepartment of Clinical Laboratory, WuHu Hospital, East China Normal University (The Second People's Hospital, WuHu), Wuhu, Anhui, China.
Shiqi YanDepartment of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jieyu ZhouDepartment of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ziying TianDepartment of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Ying LiuDepartment of Clinical Laboratory, Zhengzhou Orthopaedics Hospital, Zhengzhou, China.
Nan LiDepartment of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qing ZhouDepartment of Clinical Laboratory, First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Xiayu LiHunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Lei ShiDepartment of Pathology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Su JiangDepartment of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Mengna LiNHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital/ the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Xiao ZhouDepartment of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Donghai HuangDepartment of Otolaryngology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhaoyang ZengNHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital/ the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Songqing FanDepartment of Pathology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wei XiongNHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital/ the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Ming ZhouNHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital/ the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Guiyuan LiNHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital/ the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Wenling ZhangDepartment of Medical Laboratory Science, the Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic strategies aimed at harnessing anti-tumor immunity are being intensively investigated as they show promising results in cancer treatment. The PD-1/ PD-L1 pathway is an essential target for restoring functional anti-tumor immune response. BRD7 is a candidate tumor suppressor gene and nuclear transcription factor of nasopharyngeal carcinoma (NPC) which was cloned in our laboratory. In this paper, we reported that the candidate tumor suppressor gene BRD7 was strongly associated with good prognosis of NPC patients and negatively regulated PD-L1 expression. In addition, we found that BRD7 down-regulated PD-L1 expression and enhanced the killing function of CD8

Indexed as

B7-H1 AntigenChromosomal Proteins, Non-HistoneNasopharyngeal NeoplasmsAnimalsBromodomain Containing ProteinsCarcinomaCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansMaleMiceMice, Inbred BALB CMice, NudeNasopharyngeal CarcinomaPhosphatidylinositol 3-KinasesB7-H1 AntigenBRD7 protein, humanBromodomain Containing ProteinsCD274 protein, humanChromosomal Proteins, Non-HistonePhosphatidylinositol 3-KinasesBRD7Immune escapeNasopharyngeal carcinomaPD-L1

Identifiers

PMID40083706
PMCPMC11900823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.